Press releases – 2017– Search

Whether it is new and groundbreaking research results, university topics or events – in our press releases you can find everything you need to know about the happenings at Goethe University. To subscribe, just send an email to ott@pvw.uni-frankfurt.de

Goethe University PR & Communication Department 

Theodor-W.-Adorno Platz 1
60323 Frankfurt 
presse@uni-frankfurt.de

 

Jun 23 2017
14:44

EU funds further three networks for doctoral training at Goethe University Frankfurt

Cloud formation, infection research, ubiquitin code

FRANKFURT. The European Union is funding three new projects - Innovative Training Networks (ITN) within the Marie Sklodowska-Curie Programme - for structured doctoral training at Goethe University Frankfurt. Such projects are very attractive for universities because they are open to all scientific topics and focus on basic research.

For the CLOUD-MOTION project coordinated by atmospheric researcher Professor Joachim Curtius, Goethe University Frankfurt has been awarded funding of € 500,000. This is a follow-up project from two previous doctoral researcher networks successfully coordinated by Professor Curtius since 2008.

In CLOUD-MOTION, doctoral researchers at 10 European institutions will investigate cloud formation from aerosols and ice particles in the atmosphere and their influence on the climate. A key focus is the comparison of intact areas of the atmosphere with those polluted as a result of human activities. Research work is based on experiments in a “cloud chamber” at CERN, the European Organization for Nuclear Research, in which different situations in the atmosphere can be simulated under laboratory conditions.

The ViBrANT Network, of which Goethe University Frankfurt is a member, is an interdisciplinary team of European infection researchers leading in their field worldwide. The network is working together for a better understanding of how viruses and bacteria attach to host cells. This will form the basis for developing highly specific diagnostic procedures, whereby one of the main priorities is the development of new diagnostic detection methods for multi-resistant pathogens. The 15 doctoral researchers will become acquainted with universities and industrial partners in seven European countries during their training and this will teach them how to convert findings from basic research as rapidly as possible into usable technologies that benefit patients with infectious diseases. € 500,000 have been made available for doctoral researchers at Goethe University Frankfurt.

Goethe University Frankfurt is also involved in the UbiCODE doctoral network, which is searching for new diagnostic markers and drug targets in the ubiquitin system. This small protein found throughout the body forms unexpectedly diverse and complex chains. The contribution of these chains to the regulation of protein functions and cellular quality control is, however, far from being fully understood. Malfunctions in this system can lead to diseases such as cancer, neurodegeneration, inflammatory conditions and multiple infections. Goethe University Frankfurt’s share of the funding is € 250,000.

With the approval of the three new ITNs, the University is continuing it success of the past years in this funding line. In 2016, five new projects started work. 18 ITNs are currently underway at Goethe University Frankfurt.

Further information: CLOUD-MOTION: Prof. Dr. Joachim Curtius, Department of Atmospheric and Environmental Sciences, Faculty of Geosciences and Geography, Riedberg Campus, Tel.: +49 (0) 69 798 40258, curtius@iau.uni-frankfurt.de

ViBrANT: Prof. Dr. Volkhard Kempf, Institute of Medical Microbiology and Infection Control, Faculty of Medicine, Niederrad Campus, Tel.: +49 (0) 69 6301-5019, volkhard.kempf@kgu.de

UbiCODE: Prof. Dr. Ivan Dikic, Dr. Kerstin Koch, Institute of Biochemistry II, Faculty of Medicine, Niederrad Campus, Tel.: +49 (0)69 6301-84250, K.Koch@em.uni-frankfurt.de

 

 

Jan 10 2017
11:17

Researchers from Goethe University discover a new clinical biomarker to improve treatment of leukaemia

More individual therapy for blood cancer patients

Because it is impossible to predict which acute myeloid leukaemia (AML) patients will benefit, all patients are routinely treated with chemotherapy although only some will respond to the treatment. Researchers from Goethe-University Frankfurt have now discovered a novel biomarker that enables the detection of therapy responders and non-responders with high accuracy. In addition, their research reveals new hope for patients who currently cannot be effectively treated.

The anti-cancer drug cytarabine provides the basis of chemotherapies directed against AML. Cytarabine needs to be activated in cancer cells by the addition of phosphate groups to exert its anti-cancer effects. Prof Jindrich Cinatl (Institut für Medizinische Virologie, Goethe-Universität, Acting Director: Prof Volkhard Kempf) investigated with his research group (funded by the Frankfurter Stiftung fürkrebskranke Kinder) cytarabine-resistant AML cells from the Resistant Cancer Cell Line (RCCL) collection (www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.html) that he runs together with Prof Martin Michaelis (University of Kent, Canterbury, UK). ProfCinatl discovered that the toxicity of cytarabine against AML cells correlates with the expression of the cellular enzyme SAMHD1, which enables to predict the sensitivity of AML cells to cytarabine.

Following this initial finding, a consortium led by Prof Cinatl together with Prof Oliver Keppler (who moved from the Institut für Medizinische Virologie, Goethe-Universität to Ludwig-Maximilians-Universität, München during the project) showed that SAMHD1 removes the phosphate residues from the active form of cytarabine and thereby reverses it into its inactive state. In a cooperation with clinicians (led by Prof Hubert Serve, Medizinische Klinik II, Goethe-Universität) it was shown that SAMHD1 levels determined in leukaemia cells also enabled the prediction of the response of AML patients to cytarabine-based chemotherapies with high accuracy. This introduces SAMHD1 as clinical biomarker that can guide cytarabine-based chemotherapies only to such patients that are very likely to respond and spares patients who are unlikely to respond from toxic side effects. In addition, the Frankfurt-led team showed that inhibition of SAMHD1 effectively sensitises cytarabine-resistant AML cells to cytarabine-based chemotherapies, opening future prospects for the treatment of patients for whom currently no effective therapy exists.

The research was published in the journal Nature Medicine on 19th December 2016 and can be found here:

http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4255.html